Since their invention in the early 2000s, tyrosine kinase inhibitors (TKIs) have gained
prominence as the most effective pathway-directed anti-cancer agents. TKIs have shown …

Most reports on chronic myeloid leukaemia (CML) treatment with tyrosine kinase inhibitors
(TKIs) focus on efficacy, particularly on molecular response and outcome. In contrast …

Abstract In PACE (Ponatinib Ph+ ALL and CML Evaluation), a phase 2 trial of ponatinib that
included patients with chronic-phase chronic myeloid leukemia (CP-CML) resistant to …

Purpose Bosutinib is a potent dual SRC/ABL kinase inhibitor approved for adults with
Philadelphia chromosome–positive chronic myeloid leukemia (CML) resistant and/or …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a reciprocal
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …

Introduction: Protein kinases are involved in various cellular functions. About 2% of the
human genome encodes for protein kinases. Dysregulation of protein kinases is implicated …

For most patients with chronic myeloid leukemia, tyrosine kinase inhibitors (TKIs) have
turned a fatal disease into a manageable chronic condition. Imatinib, the first BCR-ABL1 TKI …

This analysis from the multicenter, open-label, phase 3 BFORE trial reports efficacy and
safety of bosutinib in patients with newly diagnosed chronic phase (CP) chronic myeloid …

Background The present review is part of the European Society of Clinical Microbiology and
Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) …

The past 2 decades have seen a revolution in our approach to therapeutic
immunosuppression. We have moved from relying on broadly active traditional medications …